This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Generic Drug Stocks to Watch Amid Inflation Pressures
by Sundeep Ganoria
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
New Strong Buy Stocks for November 17th
by Zacks Equity Research
PSX, DCP, RDY, PDFS and CRZBY have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2022.
Doctor Reddy's (RDY) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
by Zacks Equity Research
Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
by Zacks Equity Research
TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel
by Zacks Equity Research
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
by Sundeep Ganoria
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva
by Zacks Equity Research
Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.
Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
New Strong Sell Stocks for May 20th
by Zacks Equity Research
Teaser: CBAN, CHUY, and RDY have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2022.
New Strong Sell Stocks for May 18th
by Zacks Equity Research
ALX, CBAN, and RDY have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2022.
New Strong Sell Stocks for May 12th
by Zacks Equity Research
CHUY, RDY, and FBC have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2022.
Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure
by Indrajit Bandyopadhyay
The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.
New Strong Sell Stocks for November 22nd
by Zacks Equity Research
RDY, FRO, WWW, PGR, and LGIH have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2021.
New Strong Sell Stocks for November 4th
by Zacks Equity Research
ALX, RDY, HSC, LAWS, and ANDE have been added to the Zacks Rank #5 (Strong Sell) List on November 4, 2021.
Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y
by Zacks Equity Research
Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.
Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.
Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy
by Zacks Equity Research
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.